Pramlintide Acetate Safety Review Dragos Roman MD Center for Drug Evaluation and Research.

Slides:

Advertisements

Similar presentations

In the name of GOD In the name of GOD.

Advertisements

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Long-term Safety and Effectiveness of Natalizumab STRATA MS Study.

Update on Therapies: Clinical Trials Timothy PM Whelan Assistant Professor of Medicine Medical Director, Interstitial Lung Disease Program University of.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.

Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.

Quality of life improves after patients switch to biphasic insulin aspart 30/70 (BIAsp 30): IMPROVE™ Study data from 39,015 patients M. Benroumpi 1, T.

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.

Improving Patient Outcomes GLYCEMIC CONTROL IN PERI-OPERATIVE PATIENTS UTILIZING INSULIN INFUSION PROTOCOLS.

Extended Treatment Effects with Zoledronic Acid Based on Poster 1070 “The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized.

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

How to Analyze Therapy in the Medical Literature (part 2)

1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.

Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 5.

ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

Pramlintide Therapy Part 2 of 2 Pharmacodynamic Review Type 1 Diabetes Efficacy Safety.

A Diabetes Outcome Progression Trial

Pramlintide – An analog of amylin that overcomes the tendency of human amylin to: Aggregate, form insoluble particles Adhere to surfaces – Pharmacokinetic.

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

1 Serious Adverse Events Following Falsely Elevated Glucose Measurements Resulting from Administration of an IGIV Product Containing Maltose BPAC Meeting,

Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

1 PHOTOFRIN® PDT for High-grade Dysplasia in Barrett’s Esophagus Edvardas Kaminskas, M.D. Medical Officer, CDER, ODE III, DGCDP Milton Fan, Ph.D. Statistical.

Int J Clin Pract, December 2013, 67, 12,

Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.

What about VIOXX?. Adenomatous Polyp Prevention on Vioxx (APPROVe) Vioxx (rofecoxib) versus Placebo Basic Clinical Trial Objective: Assess whether Vioxx.

Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

Circulatory System Devices Panel Questions for Discussion EMBOL·X Aortic Filter October 23, 2002.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,

Gerti Tashko, M.D. DM Journal Club 12/16/2010. The use of exenatide with insulin is not FDA approved. The study was designed to evaluate if exenatide.

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

CLINICAL EFFICACY STUDY OF BACLOFEN IN REDUCING ALCOHOL CONSUMPTION IN HIGH RISK DRINKERS Study title: Alcohol Treatment : A Pragmatic Randomized, Double-blind.

Risk Factors for Linezolid-Associated Thrombocytopenia in Adult Patients Cristina Gervasoni Ospedale Luigi Sacco, Milano.

D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.

CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.

1 Clinical Studies Section of Labeling Joseph Porres, M.D., Ph.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA.

Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.

Diabetic hypoglycemia from prevention to management.

Neal B, et al. Diabetes Care 2015;38:403–411

Martha Carvour, MD, PhD March 2, 2017

Osborne K.B., Davies S.J., Coppini D.V.

The Impact of a Structured Balance Training Program on Elderly Adults

Empagliflozin (Jardiance®)

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

on behalf of the LEADER Trial Steering Committee and Investigators

↑- likely due to hypoglycemia and weight gain

Diabetes Journal Club Julie Shah.

Pramlintide Synthetic analog of the β-cell hormone amylin

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Guidelines for Initiation of Therapy

Pramlintide Therapy Part 1of 2

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

PowerPoint 16:9 Screen Ratio Template *

Hyperglycemic Targets & Hypoglycemia

Fresh perspectives ON BASAL Insulins in diabetes care

Presentation transcript:

Pramlintide Acetate Safety Review Dragos Roman MD Center for Drug Evaluation and Research

Pramlintide Acetate Safety Review Outline Phase 3 Trials –Motor vehicle accident (MVA)-related events Serious adverse events (SAEs) associated with hypoglycemia (type 1 diabetes) –Other accident/injury-related events Assisted hypoglycemia

Pramlintide Acetate Safety Review Outline Phase 3 Trials –Motor vehicle accident (MVA)-related events Serious adverse events (SAEs) associated with hypoglycemia (type 1 diabetes) –Other accident/injury-related events Assisted hypoglycemia

Phase 3 Clinical Trials Long-term controlled studies in patients with type 1 diabetes: – year – year – months Long-term controlled studies in patients with type 2 diabetes: – year – months – year

Phase 3 Clinical Trials (Type 1 Diabetes)

First Month Nausea-Related Withdrawals -Type 1 Diabetes % withdrawals

Phase 3 Clinical Trials (Type 2 Diabetes)

First Month Nausea-Related Withdrawals -Type 2 Diabetes % withdrawals

Pramlintide Acetate-Safety Review Outline Phase 3 Trials –Motor vehicle accident (MVA)-related events Serious adverse events (SAEs) associated with hypoglycemia (type 1 diabetes) –Other accident/injury-related events Assisted hypoglycemia

Assisted Hypoglycemia: Definition Hypoglycemic event that requires: –oral carbohydrates –glucagon –IV glucose

Assisted Hypoglycemia-Type 1 Diabetes Phase 3 Trials: First Month Incidence % patients

Assisted Hypoglycemia-Type 1 Diabetes Phase 3 Trials: End of the First Month to The End of the Trial Incidence % patients

Change in HbA1c: Study Type 1 Diabetes

Assisted Hypoglycemia-Type 1 Diabetes Phase 3 Trials: Summary Pramlintide therapy is associated with a two fold increase in incidence of assisted hypoglycemia when compared to placebo, during the first month of treatment.

Assisted Hypoglycemia-Type 1 Diabetes Phase 3 Trials: Summary The difference in incidence of assisted hypoglycemia between pramlintide and placebo groups persists following the first month of treatment albeit to a lower extent. This decrease in hypoglycemic events associated with pramlintide takes place in the context of prior nausea-related patient withdrawals and waning drug efficacy.

Assisted Hypoglycemia-Type 2 Diabetes Phase 3 Trials: First Month Incidence % patients

Assisted Hypoglycemia-Type 2 Diabetes Phase 3 Trials: End of the First Month to The End of the Trial Incidence % patients

Assisted Hypoglycemia-Type 2 Diabetes Phase 3 Trials: Summary Pramlintide therapy is associated with a three fold increase in incidence of assisted hypoglycemia when compared to placebo, during the first month of treatment.

Assisted Hypoglycemia-Type 2 Diabetes Phase 3 Trials: Summary The difference in incidence of assisted hypoglycemia between pramlintide and placebo groups wanes following the first month of treatment. This decrease takes place in the context of prior nausea-related patient withdrawals although to a lower extent than in type 1 diabetes.

Assisted Hypoglycemia : Summary The incidence of assisted hypoglycemia was higher during the type 1 and type 2 diabetes trials when compared to controls during both time intervals analyzed. Hypoglycemia associated with pramlintide was, however, more common in type 1 diabetes patients.

Pramlintide Acetate Safety Review Outline Phase 3 Trials –Motor vehicle accident (MVA)-related events Serious adverse events (SAEs) associated with hypoglycemia (type 1 diabetes) –Other accident/injury-related events Assisted hypoglycemia

Serious Adverse Events-Definition Death Life-threatening Hospitalization Disability

Deaths Possibly Related to Hypoglycemia A 48-year-old male with a 12-year history of type 1 diabetes mellitus with a prior history of “diabetes- related seizures“ died during a nocturnal hypoglycemic seizure (pramlintide 30µg QID). 35-year-old male with a 6-year history of type 1 diabetes mellitus died in a motor vehicle accident within 24 hours from the beginning of the trial. “Food was present in the stomach at the post-mortem examination, indicating that the subject had eaten lunch prior to the event.” (pramlintide 90 µg TID).

Pramlintide Acetate Safety Review Outline Phase 3 Trials –Motor vehicle accident (MVA)-related events Serious adverse events (SAEs) associated with hypoglycemia (type 1 diabetes) –Other accident/injury-related events Assisted hypoglycemia

Hypoglycemia and Accidents-Type 1 Diabetes Motor vehicle accident (MVA)-related events. Automobile-related adverse events with no motor vehicle accident reported. Other accident/injury-related events (e.g. falls, fractures, lacerations).

MVAs and Automobile-Related Adverse Events-Type 1 Diabetes (All Clinical Development Program)

Driving-Related Events Associated With Hypoglycemia -Phase 3 Trials (Type 1 Diabetes)

Driving-Related Events Associated With Hypoglycemia - Type 1 Diabetes: Conclusion Pramlintide use in addition to insulin is associated with a four fold increase in driving-related events in type 1 diabetes patients.

Other Accidents and Injuries-Type 1 Diabetes (All Clinical Development Program)

Other Accidents and Injuries-Phase 3 Trials (Type 1 Diabetes)

Other Accidents and Injuries- Type 1 Diabetes: Conclusion Pramlintide use in addition to insulin is associated with a four fold increase in non- MVA injuries in type 1 diabetes patients.

Severe Hypoglycemia: Labeling Question Do we know how to initiate safely pramlintide treatment and avoid the risk of first month hypoglycemia in both patients with type 1 and type 2 diabetes ?

Severe Hypoglycemia: Labeling Question Sponsor’s suggestions: “Initiate treatment with 30 µg or 60 µg of pramlintide per dose in type 1 diabetics and 120 µg per dose in type 2 diabetics”. FDA comments: All above doses have been shown to be associated with a two fold increased risk of assisted hypoglycemia during the phase 3 trials.

Severe Hypoglycemia: Labeling Question Sponsor’s suggestions: “In clinical practice it would be prudent to reduce the patient’s insulin dose, particularly the short-acting insulin administered preprandially by 10-20% at the time of initiation of pramlintide therapy.” FDA comments: While such an approach seems prudent it has not been tested in a clinical trial and its potential usefulness remains unknown.

Accidents Associated With Hypoglycemia-Labeling Question How can one prevent the four fold risk of driving-related events and the four fold risk of non-MVA injuries associated with hypoglycemia observed in the type 1 diabetes trials?

= pramlintide = placebo

Summary Pramlintide therapy results in a small but statistically significant reduction in HbA1c. This reduction is associated with a two fold increase of severe hypoglycemia during the first month of treatment. In addition, a four fold increase in hypoglycemia- associated MVAs and non-MVA trauma, was observed in patients with type 1 diabetes.